Bill
HB 3834
Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act; terms; requirements for drug developers; contractual terms; intellectual property rights; reports; intellectual property account; effective date.
2026 Regular Session
Introduced by Avery Frix and 1 co-sponsor
Oklahoma authorizes ibogaine clinical trials under new "Breakthrough Therapy Act," establishing IP protections and state revenue-sharing to attract addiction research despite federal Schedule I restrictions.
Placed on General Order